X4 Pharmaceuticals (XFOR) Non Operating Income (2017 - 2025)

X4 Pharmaceuticals' Non Operating Income history runs 9 years deep, the most recent figure standing at -$226000.0 for Q4 2025.

• Quarterly Non Operating Income rose 94.13% year-over-year to -$226000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.7 million (up 1145.33% YoY) and the FY2025 annual result came in at $7.7 million, up 1145.33% from the prior year.
• Non Operating Income was -$226000.0 for Q4 2025 at X4 Pharmaceuticals, up from -$2.3 million in the prior quarter.
• Across five years, Non Operating Income topped out at $24.9 million in Q3 2023 and bottomed at -$29.9 million in Q2 2023.
• A 5-year average of $178850.0 and a median of -$704000.0 in 2021 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 1825.61% in 2023, while the deepest fall reached 4585.27% in 2023.
• X4 Pharmaceuticals' Non Operating Income stood at -$1.1 million in 2021, then tumbled by 205.74% to -$3.5 million in 2022, then jumped by 273.7% to $6.1 million in 2023, then tumbled by 163.06% to -$3.8 million in 2024, then surged by 94.13% to -$226000.0 in 2025.
• Business Quant data shows XFOR's Non Operating Income at -$226000.0 in Q4 2025, -$2.3 million in Q3 2025, and $528000.0 in Q2 2025.